YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
* Seres Therapeutics press release [https://seekingalpha.com/pr/20607501-seres-therapeutics-reports-second-quarter-2026-financial-results-and-provides-business] (MCRB [https://seekingalpha.com/symbol/MCRB]): Q2 EPS of $0.47 may not be comp…
Seres Therapeutics, Inc. Agreement with Nestlé Health Science provides $25 million payable to Seres in 2026 as a buy-out of potential future VOWST™ net sales-based milestones Restructured lease materially reduces ongoing annual facility ca…
Seres Therapeutics, Inc. CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright 4th Annua…
Health care stocks were higher late Thursday afternoon, with the NYSE Health Care Index adding 0.8% PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
[An arrow pointing downwards on top of a pile of US dollar bills.] Seres Therapeutics (MCRB [https://seekingalpha.com/symbol/MCRB]) lost ~25% in the premarket on Thursday after the company announced plans to pause additional investments fo…
Data demonstrate clinical translation of VOWST mechanisms of action in both first and multiply recurrent CDI patients Seres MbTx® platform provides high-resolution functional biological understanding of live biotherapeutics and supports th…
2025 was a catalyst year for biotech and drug stocks. While the year began on a cautious note for the sector due to concerns over potential tariffs on pharmaceutical imports, the sector rebounded in the second half. Large drugmakers’ drug…
Seres Therapeutics, Inc. CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will participate in a fireside chat at the Piper…
* Seres Therapeutics press release [https://seekingalpha.com/pr/20293885-seres-therapeutics-reports-third-quarter-2025-financial-results-and-provides-business-updates] (MCRB [https://seekingalpha.com/symbol/MCRB]): Q3 GAAP EPS of $0.94 bea…
CAMBRIDGE, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a glo…
Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for the treatment of he…
[Financial advisor interacts with a digital interface displaying machine learning data insights.] QuantumScape Corporation (NYSE:QS [https://seekingalpha.com/symbol/QS]) rallied in morning trading on Thursday as it took back ground lost ov…
* Rapport Therapeutics (NASDAQ:RAPP [https://seekingalpha.com/symbol/RAPP]) priced [https://seekingalpha.com/pr/20227241-rapport-announces-pricing-of-public-offering-of-common-stock] an underwritten public offering of 9.62M shares at a pub…
(RTTNews) - Several biotech and medical technology stocks posted notable gains in after-hours trading on Monday, with momentum driven by a mix of earnings optimism, clinical trial progress, and speculative positioning. While some names ral…
* Rapport Therapeutics (NASDAQ:RAPP [https://seekingalpha.com/symbol/RAPP]) has commenced an underwritten public offering of $250M of shares of its common stock. * RAPP -5.61% after hours to $29.76. * Source: Press Release [https://seeking…
[Gut bacteria , gut flora, microbiome. Bacteria inside the small intestine, concept, representation. 3D illustration.] ChrisChrisW/iStock via Getty Images Seres Therapeutics jumped 21% in premarket trading after a report that Nestle made a…
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. [premarket] TODAY'S PRE-MARKET GAINERS TICKER CHANGE COMMENT HOUR [https://www.chartmill.com/st…
Seres Therapeutics, Inc. CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright Global I…
CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright Global Investment Conference in N…
Earnings Call Insights: Seres Therapeutics (MCRB) Q2 2025 MANAGEMENT VIEW * Marella Thorell, Co-CEO and CFO, emphasized ongoing progress in SER-155 development, stating that "our efforts and results to date have clearly demonstrated both t…
Seres Therapeutics Inc. (MCRB) reported a larger-than-expected loss for Q2 2025, with earnings per share (EPS) at -$2.27, significantly below the forecast of -$0.09. The company’s stock experienced a minor dip, reflecting investor concerns…
Seres Therapeutics Inc (NASDAQ:MCRB [https://www.chartmill.com/stock/quote/MCRB]) reported its second-quarter 2025 financial results, posting revenue of $0.0 and an earnings per share (EPS) loss of $2.27. While revenue was in line with ana…
Seres Therapeutics, Inc. Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to t…
Major earnings expected before the bell on Wednesday include: * The Walt Disney Company (DIS [https://seekingalpha.com/symbol/DIS]) * Shopify (SHOP [https://seekingalpha.com/symbol/SHOP]) * McDonald's Corporation (MCD [https://seekingalpha…
CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on August 6, 2025 at 8:…
CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, today announced the Company will be presenting new exploratory biomarker data from i…
Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support for the proposed primary efficacy endpoint of reduction in bloodstream infections (BSIs) at day 30 post-HSCT; Com…
CAMBRIDGE, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, announced today the receipt of a $50 million installment payment related to the Com…
In this article, we will be taking a look at 11 oversold NASDAQ stocks to buy right now. To skip our detailed analysis of current stock market news, you can go directly to see the 5 Oversold NASDAQ Stocks To Buy Right Now. NASDAQ Leads The…
In this article, we will be taking a look at 11 oversold healthcare stocks to buy right now. To skip our detailed analysis of the healthcare sector, you can go directly to see the 5 Oversold Healthcare Stocks To Buy Right Now. The Healthca…
CAMBRIDGE, Mass., January 17, 2024--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB) ("Seres" or the "Company"), a leading microbiome therapeutics company, today announced that on January 10, 2024, the Compensation and Talent Commi…
Halozyme Therapeutics HALO shares ended the last trading session 5.6% higher at $36.36. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 11.3% los…
VOWST preliminary net sales of approximately $10.4 million (unaudited) for the fourth quarter of 2023 Significant adoption of VOWST since commercial launch in June 2023 through year-end 2023 with 2,833 patient enrollment forms received and…
CAMBRIDGE, Mass., January 04, 2024--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will present at the 42nd Annual J.P. Morgan Healthcare Conferenc…
CAMBRIDGE, Mass., December 08, 2023--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that preliminary clinical data from a currently enrolling Phase 1b study of SER-155 s…
Key Insights Given the large stake in the stock by institutions, Seres Therapeutics' stock price might be vulnerable to their trading decisions The top 5 shareholders own 52% of the company Ownership research along with analyst forecasts d…